2020
DOI: 10.12968/jowc.2020.29.latam_sup_3.6
|View full text |Cite
|
Sign up to set email alerts
|

Prevención de lesiones cutáneas causadas por productos y equipos de protección personal durante COVID-19: revisión de alcance

Abstract: Sinopsis Objetivo: Identificar, resumir y presentar las recomendaciones publicadas para prevenir lesiones cutáneas (cualquier alteración de la piel) por el uso de productos y equipos de protección personal (EPP) en profesionales de la salud durante la pandemia del COVID-19. Método: Se realizó una revisión de alcance, basada en las sugerencias del Instituto Joanna Briggs, entre diciembre de 2019 y mayo de 2020. Se incluyeron estudios realizados con profesionales de la salud de ambos sexos, que utilizaron produc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0
4

Year Published

2020
2020
2024
2024

Publication Types

Select...
4

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(15 citation statements)
references
References 14 publications
0
7
0
4
Order By: Relevance
“…Patients with psoriasis (12 [32.4%] had also a diagnosis of psoriatic arthritis) displayed a median PASI of 5.3 2‐14 and before mask use 40% were clinically stable (<10% PASI variation in two consecutive visits). Thirty patients underwent systemic antipsoriatic therapies (15 secukinumab, 8 ixekizumab, 7 ustekinumab, 4 adalimumab, 2 apremilast, and 1 etanercept) and 13 were previously Koebner negative (no previous KB episodes).…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…Patients with psoriasis (12 [32.4%] had also a diagnosis of psoriatic arthritis) displayed a median PASI of 5.3 2‐14 and before mask use 40% were clinically stable (<10% PASI variation in two consecutive visits). Thirty patients underwent systemic antipsoriatic therapies (15 secukinumab, 8 ixekizumab, 7 ustekinumab, 4 adalimumab, 2 apremilast, and 1 etanercept) and 13 were previously Koebner negative (no previous KB episodes).…”
Section: Resultsmentioning
confidence: 99%
“…Patients with vitiligo displayed a median VASI of 8.1 4‐14 and were previously stable under topical treatments (N = 10) and NB‐UVB (N = 4). They present with active disease and increased spread of perioral (N = 13) and chin (N = 1) hypopigmented patches.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations